Synthaverse S.A. (SVE) - Total Assets
Based on the latest financial reports, Synthaverse S.A. (SVE) holds total assets worth zł298.65 Million PLN (≈ $82.19 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Synthaverse S.A. for net asset value and shareholders' equity analysis.
Synthaverse S.A. - Total Assets Trend (2010–2024)
This chart illustrates how Synthaverse S.A.'s total assets have evolved over time, based on quarterly financial data.
Synthaverse S.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Synthaverse S.A.'s total assets of zł298.65 Million consist of 15.5% current assets and 84.5% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0.3% |
| Accounts Receivable | zł35.71 Million | 12.0% |
| Inventory | zł9.72 Million | 3.3% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł1.63 Million | 0.6% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Synthaverse S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Synthaverse S.A. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Synthaverse S.A.'s current assets represent 15.5% of total assets in 2024, a decrease from 25.6% in 2010.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2024, down from 0.3% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 8.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 12.0% of total assets.
Synthaverse S.A. Competitors by Total Assets
Key competitors of Synthaverse S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Synthaverse S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.03 | 1.21 | 1.08 |
| Quick Ratio | 0.79 | 0.87 | 0.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł1.27 Million | zł9.03 Million | zł1.01 Million |
Synthaverse S.A. - Advanced Valuation Insights
This section examines the relationship between Synthaverse S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | 12.3% |
| Total Assets | zł298.62 Million |
| Market Capitalization | $61.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Synthaverse S.A.'s assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Synthaverse S.A.'s assets grew by 12.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Synthaverse S.A. (2010–2024)
The table below shows the annual total assets of Synthaverse S.A. from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł298.62 Million ≈ $82.19 Million |
+12.30% |
| 2023-12-31 | zł265.90 Million ≈ $73.18 Million |
+63.03% |
| 2022-12-31 | zł163.10 Million ≈ $44.89 Million |
+39.61% |
| 2021-12-31 | zł116.83 Million ≈ $32.15 Million |
+36.06% |
| 2020-12-31 | zł85.86 Million ≈ $23.63 Million |
+5.86% |
| 2019-12-31 | zł81.11 Million ≈ $22.32 Million |
-5.96% |
| 2018-12-31 | zł86.25 Million ≈ $23.74 Million |
-28.73% |
| 2017-12-31 | zł121.03 Million ≈ $33.31 Million |
+7.43% |
| 2016-12-31 | zł112.66 Million ≈ $31.00 Million |
-32.20% |
| 2015-12-31 | zł166.16 Million ≈ $45.73 Million |
+47.93% |
| 2014-12-31 | zł112.33 Million ≈ $30.91 Million |
+14.96% |
| 2013-12-31 | zł97.71 Million ≈ $26.89 Million |
+3.81% |
| 2012-12-31 | zł94.13 Million ≈ $25.91 Million |
-11.41% |
| 2011-12-31 | zł106.26 Million ≈ $29.24 Million |
+44.63% |
| 2010-12-31 | zł73.47 Million ≈ $20.22 Million |
-- |
About Synthaverse S.A.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more